pS2与原发性乳腺癌辅助激素治疗的反应
pS2 and response to adjuvant hormone therapy in primary breast cancer.
作者信息
Spyratos F, Andrieu C, Hacène K, Chambon P, Rio M C
机构信息
Centre René Huguenin, Saint-Cloud, France.
出版信息
Br J Cancer. 1994 Feb;69(2):394-7. doi: 10.1038/bjc.1994.73.
Abstract
We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in patients who received hormone therapy, in whom pS2 status was also predictive of the response to therapy.
摘要
我们对319例原发性乳腺肿瘤的细胞溶质pS2含量进行了回顾性研究，中位随访时间为6年。pS2状态与雌二醇和孕激素受体呈正相关，与斯卡夫、布鲁姆和理查森分级呈负相关。pS2阳性与更长的总生存期相关，尤其是在接受激素治疗的患者中，在这些患者中pS2状态也可预测对治疗的反应。
相似文献
1
pS2 and response to adjuvant hormone therapy in primary breast cancer.pS2与原发性乳腺癌辅助激素治疗的反应
Br J Cancer. 1994 Feb;69(2):394-7. doi: 10.1038/bjc.1994.73.
2
[Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].[乳腺雌激素受体阳性和孕激素受体阳性浸润性导管癌中的细胞溶质pS2水平与细胞增殖]
Rev Esp Med Nucl. 2005 May-Jun;24(3):185-90. doi: 10.1157/13073789.
3
[Analysis of the cytosolic content of the pS2 protein in breast cancer].[乳腺癌中pS2蛋白胞质含量的分析]
Rev Esp Med Nucl. 2002 Feb;21(1):28-33. doi: 10.1016/s0212-6982(02)72029-6.
4
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.纤溶酶原激活物抑制剂-1与原发性乳腺癌的预后
J Clin Oncol. 1994 Aug;12(8):1648-58. doi: 10.1200/JCO.1994.12.8.1648.
5
Prediction of relapse and survival in breast cancer patients by pS2 protein status.通过pS2蛋白状态预测乳腺癌患者的复发和生存情况。
Cancer Res. 1990 Jul 1;50(13):3832-7.
6
Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.乳腺癌中pS2蛋白阳性、类固醇受体状态与其他预后因素之间的相关性。
Int J Biol Markers. 1995 Apr-Jun;10(2):87-93. doi: 10.1177/172460089501000204.
7
PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.乳腺癌中的PS2——类固醇受体状态的替代或补充工具？446例病例评估
Br J Cancer. 1993 Aug;68(2):374-9. doi: 10.1038/bjc.1993.343.
8
Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.乳腺癌中雌激素调节的pS2蛋白的胞质水平：与肿瘤增殖活性的相关性。
Tumour Biol. 1993;14(1):30-7. doi: 10.1159/000217822.
9
Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors.可手术乳腺癌的胞浆蛋白含量与预后。与类固醇激素受体及其他预后因素的相关性。
Breast Cancer Res Treat. 1991 Dec;20(1):25-32. doi: 10.1007/BF01833354.
10
Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor.使用针对pS2、雌激素受体和孕激素受体的免疫细胞化学检测法预测乳腺癌内分泌治疗的反应
Int J Cancer. 1993 Jun 19;54(4):619-23. doi: 10.1002/ijc.2910540416.
引用本文的文献
1
TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.三叶因子3是转移性乳腺癌内分泌反应的一种有价值的预测生物标志物。
Endocr Relat Cancer. 2015 Jun;22(3):465-79. doi: 10.1530/ERC-15-0129. Epub 2015 Apr 21.
2
Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.三叶因子 1 在早期乳腺癌中的表达：对前 3 年随访期间临床结局的潜在预测指标。
Int J Med Sci. 2014 May 1;11(7):663-73. doi: 10.7150/ijms.8194. eCollection 2014.
3
mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers.雌激素诱导基因α1-抗糜蛋白酶的mRNA表达水平是浸润性乳腺癌患者早期肿瘤复发的一个预测指标。
Cancer Sci. 2004 Nov;95(11):887-92. doi: 10.1111/j.1349-7006.2004.tb02198.x.
4
Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.月经周期和绝经期间的手术时间会影响乳腺癌中pS2的水平，但不会影响组织蛋白酶D的水平。
Br J Cancer. 1999 Feb;79(5-6):909-14. doi: 10.1038/sj.bjc.6690145.
5
Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.通过随机搜索参与人类乳腺癌细胞抗雌激素耐药性的基因来鉴定BCAR3。
EMBO J. 1998 May 15;17(10):2799-808. doi: 10.1093/emboj/17.10.2799.
本文引用的文献
1
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.乳腺癌的组织学分级与预后；对1409例病例的研究，其中359例已随访15年。
Br J Cancer. 1957 Sep;11(3):359-77. doi: 10.1038/bjc.1957.43.
2
Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.PS2和组织蛋白酶D在710例人类原发性乳腺癌中的预后价值：多变量分析
J Clin Oncol. 1993 May;11(5):899-908. doi: 10.1200/JCO.1993.11.5.899.
3
pS2 is an independent factor of good prognosis in primary breast cancer.pS2是原发性乳腺癌预后良好的独立因素。
Br J Cancer. 1993 Jul;68(1):93-6. doi: 10.1038/bjc.1993.292.
4
Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.从MCF-7人乳腺癌细胞系中克隆激素调节基因的cDNA序列。
Nucleic Acids Res. 1982 Dec 20;10(24):7895-903. doi: 10.1093/nar/10.24.7895.
5
Receptors reconsidered: a 20-year perspective.受体再审视：20年的视角
Recent Prog Horm Res. 1982;38:1-40. doi: 10.1016/b978-0-12-571138-8.50006-8.
6
Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.与雌激素受体、孕激素受体及癌基因ERBB2的表达相比，pS2基因在乳腺癌亚类中的特异性表达。
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9243-7. doi: 10.1073/pnas.84.24.9243.
7
Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence.人类pS2基因的雌激素反应元件是一个不完全回文序列。
Proc Natl Acad Sci U S A. 1989 Feb;86(4):1218-22. doi: 10.1073/pnas.86.4.1218.
8
Prediction of relapse and survival in breast cancer patients by pS2 protein status.通过pS2蛋白状态预测乳腺癌患者的复发和生存情况。
Cancer Res. 1990 Jul 1;50(13):3832-7.
9
Hormone-sensitive gene expression in breast tumours.乳腺肿瘤中的激素敏感基因表达
Anticancer Res. 1990 Jan-Feb;10(1):185-8.
10
pS2 expression and response to hormonal therapy in patients with advanced breast cancer.晚期乳腺癌患者中pS2的表达及对激素治疗的反应
Cancer Res. 1991 Jan 15;51(2):624-8.
Zotero 插件